Chardan Capital Markets Starts Replimune Group (REPL) at Buy

Chardan Capital Markets analyst Geulah Livshits initiates coverage on Replimune Group (NASDAQ: REPL) with a Buy rating and a price target of $28.00.

The analyst comments "Replimune is developing HSV-1-based oncolytic viral (OV) therapies designed to stimulate multiple innate and adaptive immune pathways to trigger a robust response against a patient's tumor, and are positioned to work in combination with the increasingly-ubiquitous anti-PD1 agents. The company's pipeline contains 3 assets: 1) RP1, which expresses GM-CSF, 2) RP2, which expresses an anti-CTLA4 antibody, and 3) RP3, which expresses anti-CTLA4 along with the immune-stimulatory ligands CD40L and 4-1BBL. Replimune is currently evaluating intratumoral administration of RP1 +/- Bristol-Myers Squibb's (unrated) anti-PD1 nivolumab in the phase II portion of a phase I/II study (NCT03767348) in 4 checkpoint-responsive tumor types. Importantly, a registration-directed randomized controlled phase II study of RP1 +/- Regeneron's (unrated) anti-PD1 cemiplimab in cutaneous squamous cell carcinoma (CSCC) is set to begin "in the near term"."

For an analyst ratings summary and ratings history on Replimune Group click here. For more ratings news on Replimune Group click here.

Shares of Replimune Group closed at $12.34 yesterday.

You May Also Be Interested In

• BTIG Starts Equinix (EQIX) at Buy
• Nomura/Instinet Reinstates Eisai Co Ltd. (4523:JP) (ESALY) at Neutral
• Citi Starts Chery Automobile Co (9973:HK) at Buy